CU23938B1 - Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2 - Google Patents

Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2

Info

Publication number
CU23938B1
CU23938B1 CU2011000206A CU20110206A CU23938B1 CU 23938 B1 CU23938 B1 CU 23938B1 CU 2011000206 A CU2011000206 A CU 2011000206A CU 20110206 A CU20110206 A CU 20110206A CU 23938 B1 CU23938 B1 CU 23938B1
Authority
CU
Cuba
Prior art keywords
influenza virus
antibodies
neutralizing
influenza
molecules capable
Prior art date
Application number
CU2011000206A
Other languages
English (en)
Other versions
CU20110206A7 (es
Inventor
Mark Throsby
Robert Heinz Edward Friesen
Theodorus Hendrikus Jacobus Kawarks
Mandy Antonia Catharine Jongeneelen
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of CU20110206A7 publication Critical patent/CU20110206A7/es
Publication of CU23938B1 publication Critical patent/CU23938B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona con moléculas de unión, tales como anticuerpos monoclonales humanos que se unen a distintos virus de la influenza que comprende HA del subtipo H3, tales como H3N2, y que tienen una amplia actividad neutralizante contra dicho virus de la influenza. Se proveen moléculas de ácido nucleico que codifican los anticuerpos, sus secuencias y composiciones que los comprenden y métodos para identificarlos y producirlos. Los anticuerpos se pueden usar en el diagnóstico, profilaxis y/o tratamiento de una infección por el virus de la influenza H3N2. En una realización preferida, los anticuerpos proveen protección cruzada contra distintos subtipos, de modo tal que se pueden prevenir y/o tratar infecciones por subtipos de influenza basados en H3, H7, y/o H10.
CU2011000206A 2009-05-11 2011-11-11 Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2 CU23938B1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21589009P 2009-05-11 2009-05-11
EP09159947 2009-05-11
EP10151155 2010-01-20
PCT/EP2010/056217 WO2010130636A1 (en) 2009-05-11 2010-05-06 Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof

Publications (2)

Publication Number Publication Date
CU20110206A7 CU20110206A7 (es) 2012-10-15
CU23938B1 true CU23938B1 (es) 2013-08-29

Family

ID=42271865

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000206A CU23938B1 (es) 2009-05-11 2011-11-11 Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2

Country Status (19)

Country Link
US (2) US8470327B2 (es)
EP (1) EP2430046B1 (es)
JP (2) JP5813629B2 (es)
KR (1) KR101790354B1 (es)
CN (2) CN102448986B (es)
AR (1) AR076570A1 (es)
AU (1) AU2010247530B2 (es)
BR (1) BRPI1012749B1 (es)
CA (1) CA2761648C (es)
CU (1) CU23938B1 (es)
EA (1) EA029939B8 (es)
ES (1) ES2934102T3 (es)
IL (1) IL216222A (es)
MX (1) MX2011011331A (es)
MY (1) MY183517A (es)
NZ (1) NZ596032A (es)
SG (1) SG176003A1 (es)
TW (1) TWI589300B (es)
WO (1) WO2010130636A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
AU2004242614B2 (en) 2003-05-30 2011-09-22 Merus N.V. Fab library for the preparation of anti vegf and anti rabies virus fabs
WO2008028946A2 (en) 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN101970483A (zh) 2007-12-06 2011-02-09 达纳-法伯癌症研究公司 抗流感病毒抗体及其使用方法
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
ES2934102T3 (es) 2009-05-11 2023-02-16 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden neutralizar el virus de la gripe H3N2 y usos de las mismas
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
KR20120132506A (ko) 2010-02-18 2012-12-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
EP2596017B1 (en) 2010-07-22 2019-04-03 John W. Schrader Cross-protective antibody against influenza viral infection
US8765686B2 (en) 2010-08-03 2014-07-01 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
US20140031418A1 (en) * 2011-04-20 2014-01-30 The Trustees Of The University Of Pennsylvania Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
JP5683752B2 (ja) 2011-07-14 2015-03-11 クルセル ホランド ベー ヴェー 系統グループ１及び系統グループ２のインフルエンザａ型ウイルス、並びにインフルエンザｂ型ウイルスを中和することが可能なヒト結合分子
CN116162175A (zh) 2011-09-20 2023-05-26 西奈山伊坎医学院 流感病毒疫苗及其应用
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013059524A2 (en) * 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
EP3566714A1 (en) * 2011-11-28 2019-11-13 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR20130059721A (ko) * 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
JP6325451B2 (ja) * 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
DK2793945T3 (en) * 2011-12-05 2018-09-03 Trellis Bioscience Llc USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION
EP2822968B1 (en) 2012-03-08 2018-01-10 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
EP2800576A2 (en) 2012-03-13 2014-11-12 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
PL2838918T3 (pl) 2012-04-20 2019-11-29 Merus Nv Sposoby i środki do wytwarzania heterodimerycznych cząsteczek podobnych do ig
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP2712626A1 (en) 2012-09-28 2014-04-02 Fabentech Passive immunisation against influenza, in particular H5N1
PE20150945A1 (es) 2012-11-13 2015-06-26 Genentech Inc Anticuerpos de antihemaglutinina y metodos de uso
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
WO2014159960A1 (en) * 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR20150138236A (ko) 2013-03-14 2015-12-09 콘트라펙트 코포레이션 향상된 치료 효능을 위해 비강내로 전달되는 중화 항체에 기반한 조성물 및 방법
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
WO2014152946A2 (en) 2013-03-14 2014-09-25 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
KR101511619B1 (ko) * 2013-04-30 2015-04-13 한국생명공학연구원 개 인플루엔자 바이러스 h3n2의 ha1 단백질을 항원으로 포함하는 개 인플루엔자 바이러스 h3n2에 특이적인 혈청 진단용 키트
EA034639B1 (ru) 2013-05-30 2020-03-02 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
RU2682049C2 (ru) * 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
WO2015143339A2 (en) 2014-03-21 2015-09-24 University Of Washington Enhanced influenza hemagglutinin binders
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
US10138295B2 (en) 2014-05-13 2018-11-27 The Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof
JP7094103B2 (ja) 2014-07-10 2022-07-01 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチンおよびその使用
CA2952351C (en) 2014-07-10 2023-10-17 Antonietta IMPAGLIAZZO Influenza virus vaccines and uses thereof
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR102668588B1 (ko) * 2015-04-08 2024-05-22 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
EP3307310A2 (en) 2015-05-13 2018-04-18 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN106146657B (zh) * 2016-07-12 2020-07-17 晋明(天津)生物医药技术开发有限公司 广谱结合流感病毒a的重组抗体片段及其制备方法与应用
KR20190135000A (ko) 2017-02-28 2019-12-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Aav 벡터를 기반으로 하는 인플루엔자 백신
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SG10201912976WA (en) 2017-02-28 2020-02-27 Univ Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
AU2018351209B2 (en) * 2017-10-18 2022-11-24 Xiamen University Mutant of H3N2 subtype influenza virus hemagglutinin protein and use thereof
ES2926243T3 (es) * 2018-01-23 2022-10-24 Janssen Vaccines & Prevention Bv Vacunas contra virus de la gripe y usos de las mismas
BR112020014849A2 (pt) 2018-01-26 2020-12-08 Regeneron Pharmaceuticals, Inc. Anticorpo recombinante isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma de infecção por influenza
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN114430742A (zh) 2019-09-05 2022-05-03 扬森疫苗与预防公司 流感病毒疫苗及其用途
EP4031558A4 (en) * 2019-09-20 2023-05-31 Academia Sinica CHIMERIC HEMAGGLUTININ PROTEIN AND VACCINE COMPOSITION COMPRISING THEM
CA3198903A1 (en) * 2019-12-13 2021-03-19 Autonomous Medical Devices Inc. Apparatus and method for point-of-care, rapid, field-deployable diagnostic testing of covid-19, viruses, antibodies and markers
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
KR20230117157A (ko) 2020-12-01 2023-08-07 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 조직 특이적 표적화 모티프를 갖는 신규 조성물 및 이를 포함하는 조성물
JP2024515788A (ja) 2021-04-27 2024-04-10 ジェネレーション バイオ カンパニー 治療抗体を発現する非ウイルスｄｎａベクター及びその使用
AU2023235112A1 (en) 2022-03-14 2024-10-17 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ATE230850T1 (de) 1996-10-08 2003-01-15 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
MXPA01010360A (es) 1999-04-15 2004-04-05 Crucell Holland Bv Produccion de proteinas recombinantes en una celula humana.
DK1402025T3 (da) 2001-06-15 2006-06-06 Crucell Holland Bv Kimære fager
DE102004037820A1 (de) * 2004-08-04 2006-03-16 Epcos Ag Elektrische Schaltung und Bauelement mit der Schaltung
DK1974017T4 (da) 2005-12-09 2023-09-25 Academisch Medisch Centrum Bij De Univ Van Amsterdam Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler
US8148085B2 (en) * 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
AU2007249160B2 (en) * 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
WO2008028946A2 (en) 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
EP2201039B1 (en) 2007-09-13 2015-07-15 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
FR2921928B1 (fr) * 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
CN101970483A (zh) * 2007-12-06 2011-02-09 达纳-法伯癌症研究公司 抗流感病毒抗体及其使用方法
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ES2934102T3 (es) * 2009-05-11 2023-02-16 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden neutralizar el virus de la gripe H3N2 y usos de las mismas

Also Published As

Publication number Publication date
TW201043248A (en) 2010-12-16
SG176003A1 (en) 2011-12-29
TWI589300B (zh) 2017-07-01
MY183517A (en) 2021-02-24
IL216222A0 (en) 2012-01-31
US9611317B2 (en) 2017-04-04
CU20110206A7 (es) 2012-10-15
US20150175677A9 (en) 2015-06-25
US20130309248A1 (en) 2013-11-21
CN105418757A (zh) 2016-03-23
BRPI1012749A8 (pt) 2021-03-09
KR20120034628A (ko) 2012-04-12
EA029939B8 (ru) 2021-04-21
CN102448986B (zh) 2015-11-25
AR076570A1 (es) 2011-06-22
BRPI1012749B1 (pt) 2022-01-11
MX2011011331A (es) 2011-11-18
AU2010247530B2 (en) 2016-10-13
CN102448986A (zh) 2012-05-09
EP2430046B1 (en) 2022-09-28
IL216222A (en) 2016-11-30
JP2012526526A (ja) 2012-11-01
KR101790354B9 (ko) 2017-10-25
WO2010130636A1 (en) 2010-11-18
AU2010247530A1 (en) 2011-11-03
EA201171383A1 (ru) 2012-05-30
JP5813629B2 (ja) 2015-11-17
CA2761648C (en) 2019-03-12
US8470327B2 (en) 2013-06-25
BRPI1012749A2 (pt) 2020-11-17
NZ596032A (en) 2013-09-27
EP2430046A1 (en) 2012-03-21
CN105418757B (zh) 2019-07-09
CA2761648A1 (en) 2010-11-18
ES2934102T3 (es) 2023-02-16
KR101790354B1 (ko) 2017-10-25
EA029939B1 (ru) 2018-06-29
JP2016040261A (ja) 2016-03-24
US20120039898A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
CU20110206A7 (es) Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CY1119896T1 (el) Μεθοδοι για αγωγη toy hcv
UY33897A (es) Inhibidores del virus de la hepatitis c
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201500854A1 (ru) Композиция, содержащая по меньшей мере две связывающие молекулы, нейтрализующие вирус гриппа а
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
ECSP14013315A (es) Inhibidores de aplicación viral
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201270616A1 (ru) Ингибиторы вируса гепатита с
EA201490288A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
EA201591761A1 (ru) Композиции на основе наночастиц
UY34066A (es) Inhibidores del virus de la hepatitis c
GT201500005A (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
EA201491581A1 (ru) Везикулярные композиции

Legal Events

Date Code Title Description
FG Grant of patent